Recent Patents on the Development of c-Met Kinase Inhibitors.

CONCLUSION: c-Met kinase inhibitors have emerged as exciting new drug classes in the treatment of all kinds of cancers, especially the Non-Small Cell Lung Cancer (NSCLC) with tumor resistance. More attention should be paid on the natural product to find novel c-Met kinase inhibitors. PMID: 32603284 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32603284?dopt=Abstract

Source: Recent Patents on Anti-Cancer Drug Discovery - July 1, 2020 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research